Emergent BioSolutions (NYSE: EBS) SVP awarded 44,834 stock options

Rhea-AI Filing Summary

Emergent BioSolutions senior vice president William Hartzel reported routine equity compensation transactions. On March 5, 2026, 9,493 shares of common stock were disposed of at $8.44 per share to cover taxes tied to restricted stock unit vesting, leaving him with 87,188 shares of common stock held directly.

On March 3, 2026, he received a grant of 44,834 employee stock options, increasing his directly held options to 259,545. The grant is scheduled to vest in three equal installments beginning on the day prior to each anniversary of the grant date.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Hartzel William

Role SVP, Bioservices

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	9,493	$8.44	$80K
Grant/Award	Employee Stock Option (Right to buy)	44,834	$0.00	--

Holdings After Transaction: Common Stock — 87,188 shares (Direct); Employee Stock Option (Right to buy) — 259,545 shares (Direct)

Footnotes (1)

1. Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units Vests in three equal installments beginning on the day prior to the anniversary date of the grant.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hartzel William

(Last) (First) (Middle)

300 PROFESSIONAL DRIVE

(Street)

GAITHERSBURG MD 20879

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Emergent BioSolutions Inc. [ EBS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Bioservices

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/05/2026		F		9,493(1)	D	$8.44	87,188	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to buy)	$8.99	03/03/2026		A		44,834		(2)	03/02/2033	Common Stock	44,834	$0	259,545	D

Explanation of Responses:

1. Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units

2. Vests in three equal installments beginning on the day prior to the anniversary date of the grant.

Remarks:

	/s/ Richard S. Lindahl, Attorney-in-fact	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did EBS executive William Hartzel report on this Form 4?

He reported a tax-related share disposition and a new option grant. 9,493 common shares were withheld to cover taxes on restricted stock unit vesting, and he received 44,834 employee stock options that vest in three equal annual installments.

How many Emergent BioSolutions (EBS) shares does William Hartzel hold after these transactions?

After the tax-withholding disposition, he holds 87,188 shares of Emergent BioSolutions common stock directly. This figure reflects his ownership following the 9,493-share disposition used to pay taxes on restricted stock unit vesting.

What are the details of the stock options granted to EBS SVP William Hartzel?

He was granted 44,834 employee stock options, recorded at a transaction price of $0.00 on the grant date. These options vest in three equal installments, starting the day before each anniversary of the grant, and raise his option holdings to 259,545.

Was William Hartzel’s share disposition in EBS stock an open-market sale?

No, the 9,493-share disposition was for tax withholding. The filing notes the shares were withheld to pay taxes associated with the vesting and settlement of restricted stock units, rather than being sold in a market transaction.

What role does William Hartzel hold at Emergent BioSolutions (EBS)?

He serves as Senior Vice President, Bioservices, at Emergent BioSolutions. The Form 4 lists him as an officer with this title while reporting his equity compensation transactions in company common stock and employee stock options.